Kairos Pharma, Ltd. (KAPA)
Develops experimental cancer drugs that boost the immune system to fight tumors.
$0.31-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-66.5%
The outlook
KAPA is trading near its 52-week low with analyst coverage showing strong buy ratings and a notably high average price target. The stock sits well below both its 50- and 200-day moving averages, indicating a weak near-term trend despite the bullish analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +2173% vs current price
Analyst price target
~12-month · 2 analysts$7.00average target+2172.7% vs now
Now $0.31
Low $2.00High $12.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.6M
52-wk high
$2.11
52-wk low
$0.27
50-day avg
$0.41
200-day avg
$0.66
Trailing P/E
—